Abstract
Metastatic bone disease is often associated with severe pain in cancer patients, and has become an increasingly important quality-of-life issue. Radionuclides, such as strontium-89 (Sr-89), have provided effective palliation of metastatic bone pain. Although strontium follows the biochemical pathways of calcium in the body, changes in calcium homeostasis related to Sr-89 therapy have rarely been reported. We present a case of a 32-year-old male with poorly differentiated neuroendocrine carcinoma and extensive skeleton metastases who developed profound hypocalcemia after Sr-89 administration.
Original language | English (US) |
---|---|
Pages (from-to) | 923-929 |
Number of pages | 7 |
Journal | Journal of pain and symptom management |
Volume | 37 |
Issue number | 5 |
DOIs | |
State | Published - May 2009 |
Keywords
- Bone metastases
- calcium-sensing receptor
- hypocalcemia
- hypoparathyroidism
- strontium-89
ASJC Scopus subject areas
- General Nursing
- Clinical Neurology
- Anesthesiology and Pain Medicine